DDX4 Antibody

What is DDX4 and why is it significant in research applications?

DDX4 has several key research applications:

• Cancer progression and chemoresistance studies

• Antiviral immunity investigations

• Germ cell identification and isolation

• Stem cell research, particularly regarding oogonial stem cells

The protein contains several functional domains that can be targeted by different antibodies depending on the research application.

How should researchers validate DDX4 antibody specificity?

Validation should include multiple complementary approaches:

• Genetic controls: Compare antibody staining between wild-type and DDX4-knockout/knockdown samples. Studies show DDX4-KO cells display significantly reduced antibody signals compared to control cells .

• Epitope blocking: Pre-incubate the antibody with immunizing peptide before application to samples.

• Multiple antibody comparison: Use antibodies targeting different DDX4 epitopes. For example, both C-terminal and N-terminal antibodies should yield similar patterns in internal DDX4 detection .

• Positive tissue controls: Include known DDX4-expressing tissues (ovary/testis) as positive controls.

• Western blot validation: Confirm antibody detects a single band of expected size (~80kDa) in expressing tissues/cells .

What are the recommended fixation and preparation methods for DDX4 immunostaining?

Fixation methods significantly impact DDX4 detection:

For optimal antigen retrieval in formalin-fixed tissues, simmer in 0.01M sodium citrate for 20 minutes before antibody application . For dual detection of surface and internal DDX4, sequential staining protocols with appropriate permeabilization steps between antibody applications yield best results.

How does DDX4 localization change in different cellular contexts and disease states?

DDX4 displays context-dependent localization patterns:

• Germline cells: Primarily cytoplasmic with RNA processing bodies.

• Cancer cells:

  • Cytoplasmic distribution with enrichment on mitotic apparatus during M phase (observed in THP-1 and IM-9 cells) .

  • Cell surface expression in certain cancer cells, particularly the C-terminus .

• Upon viral infection:

  • Increased expression following interferon stimulation .

  • Redistribution within the cell to sites of viral replication.

• Drug-resistant cancer cells:

  • DDX4 overexpression correlates with altered cellular morphology including extended filopodia and flattened shape with increased Cortactin expression .

In SCLC patients, higher DDX4 expression correlates with decreased survival and increased immune/inflammatory response markers .

What experimental approaches can resolve the controversy regarding DDX4 cell surface expression?

This remains a contentious area requiring multiple orthogonal approaches:

• Epitope-tagged constructs: Generate expression constructs with distinct N- and C-terminal tags (e.g., FLAG-DDX4-myc) to determine orientation across membranes. Study by White et al. used this approach to confirm C-terminal surface exposure .

• Non-permeabilized vs. permeabilized immunostaining: Compare staining patterns under both conditions to distinguish surface from internal protein pools.

• Surface biotinylation: Biotinylate surface proteins followed by DDX4 immunoprecipitation to confirm membrane localization.

• Live-cell imaging: Use fluorescently-tagged antibodies against the C-terminus in live, non-permeabilized cells.

• Flow cytometry validation: Perform FACS analysis on non-permeabilized cells using C-terminal antibodies followed by RT-PCR confirmation of DDX4 expression in sorted populations .

What technical considerations are important when using DDX4 antibodies for FACS-based cell isolation?

When using DDX4 antibodies for cell sorting:

• Antibody selection: Choose antibodies targeting the putative extracellular domain (C-terminus) for live cell isolation. The LS-C97782 and ab13840 antibodies have been successfully used for this purpose .

• Titration optimization: Determine optimal antibody concentration through titration experiments to minimize background while maintaining sensitivity.

• Validation controls:

  • Include FMO (Fluorescence Minus One) controls

  • Use cells transfected with DDX4 expression constructs as positive controls

  • Include isotype-matched irrelevant antibodies

• Sorted cell verification: Confirm DDX4 expression in sorted populations using RT-PCR and immunostaining in permeabilized cells .

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to minimize non-specific binding.

How can researchers experimentally assess DDX4's contribution to chemoresistance?

Several methodological approaches have proven effective:

• Generate DDX4-modified cell lines:

  • DDX4-overexpressing (DDX4-OE) cells

  • DDX4-knockout/knockdown cells via CRISPR-Cas9 or siRNA

• Drug sensitivity assays:

  • Compare IC50 values between DDX4-OE, wild-type, and DDX4-KO cells for various chemotherapeutics

  • Time-course studies of cell viability following drug exposure

  • Colony formation assays post-treatment

• In vivo xenograft models:

  • Implant DDX4-OE and control cells in immunocompromised mice

  • Administer chemotherapeutic agents (e.g., cisplatin)

  • Monitor tumor growth and survival

Research shows DDX4-OE tumors maintain growth even with cisplatin treatment, while control tumors show significantly reduced growth. DDX4-depleted cells display increased sensitivity to cisplatin .

• Mechanistic investigation:

  • Assess DNA damage response markers (γH2AX, comet assay)

  • Measure apoptotic markers (cleaved caspase-3, PARP)

  • Analyze cytokine profiles before and after treatment

Studies reveal DDX4-depleted cells show global increases in cytokine secretion after cisplatin treatment, while DDX4-OE cells show repressed cytokine response .

What molecular pathways does DDX4 regulate in cancer cells, and how can these be studied?

DDX4 regulates multiple pathways in cancer cells:

• DNA repair pathways:

  • Proteomic analysis identifies upregulation of DNA repair proteins in DDX4-OE cells

  • Measure DNA damage through γH2AX foci formation, comet assays

  • Assess repair kinetics following cisplatin-induced DNA damage

• Immune/inflammatory response:

  • Multiplex cytokine analysis shows differential cytokine profiles in DDX4-OE vs. DDX4-depleted cells

  • RT-qPCR for key immune signaling components (STAT1, CXCL10) shows upregulation in DDX4-depleted cells after cisplatin treatment

  • Pro-survival factor IL-8 is downregulated in DDX4-depleted cells after treatment

• Cell motility pathways:

  • Time-lapse imaging and automated tracking reveals increased motility in DDX4-OE cells

  • Immunostaining for motility markers shows increased Cortactin expression in DDX4-OE cells

  • DDX4-OE alters cell morphology with extended filopodia and flattened shape

• Translational regulation:

  • Polysome profiling to assess translational efficiency

  • Ribosome profiling to identify specific mRNAs regulated by DDX4

  • RNA immunoprecipitation to identify direct RNA targets

How do you design experiments to investigate DDX4's potential as a therapeutic target in cancer?

A comprehensive experimental approach includes:

• Target validation studies:

  • Analyze DDX4 expression across patient samples (correlation with survival/prognosis)

  • Perform cellular dependency screens (effect of DDX4 depletion on various cancer types)

  • Assess effects of DDX4 modulation on tumor growth in vivo

• Developing inhibition strategies:

  • Structure-function analysis to identify critical domains for DDX4 activity

  • Small molecule screening to identify compounds disrupting DDX4 helicase activity

  • Peptide inhibitors designed to interfere with DDX4 protein-protein interactions

• Combination therapy assessment:

  • Test DDX4 inhibition combined with standard chemotherapeutics

  • Evaluate potential synergistic effects with immunotherapy

  • Study combinations with DNA damage response inhibitors

Research indicates DDX4 depletion compromised in vivo tumor development, while DDX4-OE enhanced tumor growth even after cisplatin treatment in nude mice . This suggests potential therapeutic benefit from DDX4 targeting, especially in combination with conventional chemotherapy.

How does DDX4 contribute to antiviral immunity, and what experimental approaches can assess this function?

Recent studies reveal DDX4 enhances antiviral activity through several mechanisms:

• DDX4 as an interferon-stimulated gene (ISG):

  • DDX4 expression is significantly upregulated by type I interferon stimulation

  • Induction depends on STAT1 signaling pathway (STAT1 knockout blocks DDX4 upregulation)

• Experimental approaches to study antiviral function:

  Approach	Methodology	Findings
  Gene modification	Create DDX4 KO/OE cell lines	DDX4-/- cells show higher viral protein/RNA levels; DDX4 OE inhibits viral replication
  Viral challenge assays	Infect modified cells with various viruses (VSV, H1N1, SeV, HSV)	DDX4 provides broad-spectrum antiviral protection in a dose-dependent manner
  Viral kinetics	Time-course infection studies	DDX4-/- cells exhibit faster viral growth kinetics than wild-type cells
  Visualizing infection	GFP-tagged virus quantification	Number of cells infected by VSV-GFP diminished with increasing DDX4 expression

• Mechanistic investigation:

  • Analyze type I interferon signaling pathway components

  • Assess viral RNA recognition and processing

  • Examine interaction with other antiviral factors

What protocol modifications are necessary when studying DDX4 in primary immune cells versus established cell lines?

When transitioning from cell lines to primary immune cells:

• Isolation and culture considerations:

  • Primary cells require gentler isolation protocols to maintain viability

  • Shorter culture periods (24-48 hours) are optimal for many primary immune cells

  • Supplement media with appropriate cytokines to maintain cell viability without activation

• Antibody optimization:

  • Titrate antibodies specifically for primary cells (often requiring higher concentrations)

  • Perform blocking steps with species-matched normal serum to reduce background

  • Include additional negative controls from DDX4-negative tissues

• Fixation protocol adjustments:

  • Reduce fixation times for primary cells (typically 5-8 minutes vs. 10+ minutes for cell lines)

  • Lower permeabilization agent concentrations to preserve delicate primary cell structures

  • Consider alternative fixatives (e.g., 2% PFA instead of 4%) for sensitive primary cells

• Functional assays:

  • Adjust viral MOI (multiplicity of infection) downward for primary cells

  • Extend sampling timepoints to capture delayed kinetics in primary cells

  • Include cell viability assays at each timepoint

How can researchers troubleshoot inconsistent DDX4 antibody staining patterns?

Common issues and solutions include:

• Epitope masking:

  • Problem: Fixation can mask epitopes

  • Solution: Test multiple antigen retrieval methods (heat-induced vs. enzymatic); for citrate-based retrieval, simmer in 0.01M sodium citrate for 20 minutes

• Antibody specificity:

  • Problem: Cross-reactivity with similar DEAD-box helicases

  • Solution: Validate using knockout controls; perform competitive binding assays with immunizing peptide

• Cellular heterogeneity:

  • Problem: Variable DDX4 expression within a population

  • Solution: Use single-cell approaches (flow cytometry, single-cell RNA-seq); implement image cytometry to quantify expression levels across cell populations

• Subcellular localization discrepancies:

  • Problem: Different staining patterns between studies

  • Solution: Use epitope-tagged constructs with known localization domains; perform fractionation experiments to confirm antibody detection in specific cellular compartments

• Low expression levels:

  • Problem: Weak signal, especially in non-germline tissues

  • Solution: Implement signal amplification (tyramide signal amplification, indirect immunofluorescence with amplification steps); extend primary antibody incubation (overnight at 4°C)

What are the most effective extraction methods for preserving DDX4 protein integrity in different sample types?

Extraction protocols must be tailored to sample types:

• Cell lines:

  • RIPA buffer supplemented with RNase inhibitors preserves DDX4-RNA interactions

  • Include protease inhibitor cocktails to prevent degradation

  • Mild sonication (3-5 pulses) aids extraction while preserving protein integrity

• Tissue samples:

  • Fresh tissues: Immediate homogenization in ice-cold lysis buffer with RNase inhibitors

  • Frozen tissues: Cryopulverization prior to extraction enhances yield while maintaining protein structure

  • FFPE samples: Extended deparaffinization followed by specialized extraction buffers with heat treatment

• Subcellular fractionation:

  • Gentle detergent-based methods for membrane vs. cytoplasmic separation

  • Specialized nuclear extraction buffers for nuclear DDX4 pools

  • Density gradient separation for isolating DDX4-containing RNP complexes

• Preservation considerations:

  • Avoid repeated freeze-thaw cycles

  • Store aliquots in the presence of glycerol (20%) at -80°C

  • Include reducing agents (DTT or β-mercaptoethanol) in storage buffers

How can conflicting research findings on DDX4 function be reconciled through improved experimental design?

Reconciling conflicting findings requires:

• Standardized model systems:

  • Establish consensus cell lines and experimental conditions

  • Create repository of validated DDX4 constructs and antibodies

  • Develop standardized reporting of DDX4 variants and mutations

• Multi-level validation:

  • Combine genetic approaches (knockout/knockdown) with pharmacological inhibition

  • Verify findings across multiple cell types and primary tissues

  • Use complementary techniques to assess each functional endpoint

• Context-specific analysis:

  • Systematically evaluate DDX4 function under different cellular stresses (e.g., DNA damage, viral infection)

  • Assess tissue-specific regulatory factors that might influence DDX4 activity

  • Consider developmental timing and cellular differentiation state

• Careful consideration of DDX4 variants:

  • Studies reveal mutations in DDX4 genomic loci in cancer cell lines (100% in certain lines)

  • Document and report specific DDX4 splice variants or mutations present in experimental systems

  • Functionally validate the impact of specific variants on DDX4 activity

• Improved reporting and data sharing:

  • Detailed methods sections specifying antibody catalog numbers, dilutions, and validation steps

  • Raw data deposition in public repositories

  • Standardized nomenclature for DDX4 domains and modifications

By implementing these approaches, researchers can better understand context-dependent DDX4 functions and resolve apparent contradictions in the literature.